An Assessment of Survival Outcomes Among Ovarian Cancer Patients at the National and Referral Hospital in Kenya

Overview

Journal Cancer Rep (Hoboken)

Specialty Oncology

Date 2024 Feb 14

PMID 38351536

Authors

Diana Bironga Mayenga

Amsalu Degu

Affiliations

Soon will be listed here.

Abstract

Background: Ovarian cancer has been shown to have poor survival outcomes attributed to late presentation. In Kenya, information on the survival outcomes of ovarian cancer patients is scarce. Therefore, the objective of this study was to examine the survival outcomes among patients with ovarian cancer treated at Kenyatta National Hospital (KNH).

Aims: A hospital-based retrospective cohort study was performed at KNH to examine the survival outcomes of 112 ovarian cancer patients. The study employed a structured data abstraction tool to acquire patients' relevant socio-demographic and clinical characteristics from the patient's medical records. The data obtained were analyzed using SPSS version 29.0 statistical software. Kaplan-Meier and Cox regression analyses were used to determine the survival outcome and predictors of mortality among ovarian cancer patients, respectively.

Methods And Results: The mean age of the patients in this study was 51.28 ± 14.24 years. Most patients (59.8%) had evidence of distant metastasis during the follow-up period. One-third (33%) of patients were deceased. The mean-cancer-specific survival time among the study participants was 40.0 ± 3.0 months. The 5-year survival rate was 44%, with most patients experiencing disease progression during the last follow-up. Combination therapy (p < .001) was the only statistically significant predictor of mortality in ovarian cancer patients.

Conclusion: The study found that the 5-year survival rate among ovarian cancer patients was poor, with most patients experiencing disease progression during the last follow-up period.

Citing Articles

An assessment of survival outcomes among ovarian cancer patients at the National and Referral Hospital in Kenya.

Mayenga D, Degu A Cancer Rep (Hoboken). 2024; 7(2):e1986.

PMID: 38351536 PMC: 10864719. DOI: 10.1002/cnr2.1986.

References

Berek J, Renz M, Kehoe S, Kumar L, Friedlander M . Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021; 155 Suppl 1:61-85. PMC: 9298325. DOI: 10.1002/ijgo.13878. View

Arora N, Talhouk A, McAlpine J, Law M, Hanley G . Long-term mortality among women with epithelial ovarian cancer: a population-based study in British Columbia, Canada. BMC Cancer. 2018; 18(1):1039. PMC: 6202883. DOI: 10.1186/s12885-018-4970-9. View

Kajiyama H, Shibata K, Mizuno M, Umezu T, Suzuki S, Sekiya R . Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology. J Gynecol Oncol. 2014; 25(1):43-50. PMC: 3893674. DOI: 10.3802/jgo.2014.25.1.43. View

Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A . Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021; 71(3):209-249. DOI: 10.3322/caac.21660. View

Sharma R, Aashima , Nanda M, Fronterre C, Sewagudde P, Ssentongo A . Mapping Cancer in Africa: A Comprehensive and Comparable Characterization of 34 Cancer Types Using Estimates From GLOBOCAN 2020. Front Public Health. 2022; 10:839835. PMC: 9082420. DOI: 10.3389/fpubh.2022.839835. View

Degu A, Karimi P, Opanga S, Nyamu D . Predictors of survival outcomes among patients with gastric cancer in a leading tertiary, teaching and referral hospital in Kenya. Cancer Med. 2022; 12(4):4147-4160. PMC: 9972118. DOI: 10.1002/cam4.5275. View

Moraa F, Degu A . Survival Outcomes Among Pancreatic Cancer Patients at Kenyatta National Hospital. J Gastrointest Cancer. 2021; 53(4):958-964. DOI: 10.1007/s12029-021-00723-w. View

Forstner R . Early detection of ovarian cancer. Eur Radiol. 2020; 30(10):5370-5373. PMC: 7476911. DOI: 10.1007/s00330-020-06937-z. View

Armstrong D, Alvarez R, Bakkum-Gamez J, Barroilhet L, Behbakht K, Berchuck A . Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021; 19(2):191-226. DOI: 10.6004/jnccn.2021.0007. View

10.

Momenimovahed Z, Tiznobaik A, Taheri S, Salehiniya H . Ovarian cancer in the world: epidemiology and risk factors. Int J Womens Health. 2019; 11:287-299. PMC: 6500433. DOI: 10.2147/IJWH.S197604. View

11.

Elias K, Guo J, Bast Jr R . Early Detection of Ovarian Cancer. Hematol Oncol Clin North Am. 2018; 32(6):903-914. PMC: 6376972. DOI: 10.1016/j.hoc.2018.07.003. View

12.

Piatek S, Panek G, Lewandowski Z, Bidzinski M, Piatek D, Kosinski P . Rising serum CA-125 levels within the normal range is strongly associated recurrence risk and survival of ovarian cancer. J Ovarian Res. 2020; 13(1):102. PMC: 7469284. DOI: 10.1186/s13048-020-00681-0. View

13.

Moro F, Pasciuto T, Djokovic D, Di Legge A, Granato V, Moruzzi M . Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses. Ultrasound Obstet Gynecol. 2018; 53(1):116-123. DOI: 10.1002/uog.19174. View

14.

Tetsche M, Dethlefsen C, Pedersen L, Sorensen H, Norgaard M . The impact of comorbidity and stage on ovarian cancer mortality: a nationwide Danish cohort study. BMC Cancer. 2008; 8:31. PMC: 2266760. DOI: 10.1186/1471-2407-8-31. View

15.

Menon U, Gentry-Maharaj A, Burnell M, Singh N, Ryan A, Karpinskyj C . Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet. 2021; 397(10290):2182-2193. PMC: 8192829. DOI: 10.1016/S0140-6736(21)00731-5. View

16.

Mayenga D, Degu A . An assessment of survival outcomes among ovarian cancer patients at the National and Referral Hospital in Kenya. Cancer Rep (Hoboken). 2024; 7(2):e1986. PMC: 10864719. DOI: 10.1002/cnr2.1986. View

17.

Koene R, Prizment A, Blaes A, Konety S . Shared Risk Factors in Cardiovascular Disease and Cancer. Circulation. 2016; 133(11):1104-14. PMC: 4800750. DOI: 10.1161/CIRCULATIONAHA.115.020406. View

18.

Levy T, Weiser R, Boaz M, Ben Shem E, Golan A, Menczer J . Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response. Int J Gynecol Cancer. 2012; 22(8):1344-8. DOI: 10.1097/IGC.0b013e3182691254. View

19.

Harding J, Sooriyakumaran M, Anstey K, Adams R, Balkau B, Brennan-Olsen S . Hypertension, antihypertensive treatment and cancer incidence and mortality: a pooled collaborative analysis of 12 Australian and New Zealand cohorts. J Hypertens. 2015; 34(1):149-55. DOI: 10.1097/HJH.0000000000000770. View

20.

Iyoke C, Ugwu G, Ezugwu E, Onah N, Ugwu O, Okafor O . Incidence, pattern and management of ovarian cancer at a tertiary medical center in enugu, South East Nigeria. Ann Med Health Sci Res. 2013; 3(3):417-21. PMC: 3793451. DOI: 10.4103/2141-9248.117947. View